Journal of the National Cancer Institute · Nov 10, 2026
Pretreatment cognitive screening, treatment tolerability, and early mortality in older adults with advanced cancer initiating systemic therapy
By Mohamed M, Magnuson A, Chen Y et al.
BACKGROUND: Abnormal cognitive screening is common among older adults, yet its implications for cancer treatment tolerability remain unclear. We evaluated the association between pretreatment cognitive screening, treatment tolerability, and mortality among older adults with advanced cancer initiating systemic therapy. METHODS: This is a secondary analysis of the usual-care arm of the GAP70+ cluster-randomized clinical trial (NCT02054741). Participants were adults aged ≥70 years with incurable stage III/ IV solid tumors or lymphoma initiating high-risk systemic therapy. Pretreatment cognitive screening was assessed using Mini-Cog. Outcomes included grade 3-5 non-hematologic toxicity, unplanned hospitalization, and early treatment discontinuation within 3 months, and all-cause mortality at 6 months and 1 year. Multivariable logistic and Cox models adjusted for sociodemographic, clinical, and geriatric variables. RESULTS: Among 368 patients (mean age 77.2 years), 32% had abnormal cognitive screening. Abnormal screening was associated with higher odds of unplanned hospitalization (OR = 1.79, 95% CI, 1.04-3.10). Age modified this association, with stronger effects among patients aged 70-79 years (OR = 3.16, 95% CI, 1.57-6.46) but not ≥80 years (OR = 0.72, 95% CI, 0.25-1.99). Abnormal screening was also associated with increased mortality at 6 months (HR = 1.94, 95% CI, 1.24-3.03) and 1 year (HR = 1.61, 95% CI, 1.16-2.24), but not with toxicity or early discontinuation. CONCLUSIONS: Abnormal cognitive screening was associated with increased hospitalization and early mortality among older adults with advanced cancer receiving systemic therapy. Routine cognitive screening may improve risk stratification and treatment planning.